Mikroliz Therapeutic Bacteriophage Bank (MTBB)
Mikroliz is a preclinical-stage biotech company to treat multidrug resistant bacterial infections. Mikroliz Therapeutic Bacteriophage Bank (MTBB) is established in Turkey which currently has over 300 phages against mainly ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.) pathogens and other life-threatening bacterial infections.
Patent : WO2020139279 – ACINETOBACTER BAUMANNII BACTERIOPHAGE OR LYTIC PROTEIN DERIVED FROM THE BACTERIOPHAGE
MTBB is constantly growing with new phages and we are developing quick methods for phage isolation and characterization.